AMPK Signaling Activator IX, F17

A cell-permeable 4-hydroxy-2-oxo quinoline carboxamide that acts as an agonist of AMPK signaling. It is shown to reduce fat storage in C. elegans (EC₅₀ ~ 0.1 µM) and reduce the expression level of fat-7 (a C. elegans ortholog of mammalian stearoyl-CoA desaturase-1), through aak-1 (an ortholog for the AMPK-α1 catalytic subunit) and K08F8.2 (a transcription factor) dependent mechanisms. In addition, it markedly reduces the number of lipid droplets in HepG2 human hepatocarcinoma cells at 25 µM, and elicits the phosphorylation and inactivation of acetyl coenzyme A carboxylase (ACC, the enzyme that catalyzes the rate-limiting step in de novo fatty acid synthesis). F17-induced ACC phosphorylation can be abrogated by simultaneous treatment with an AMPK inhibitor compound C (Cat. No. 171260).

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Warming to 55-60°C is required for complete solubilization.

Lemieux, G.A., et al. 2011. Nat. Chem. Biol.7, 206.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Standard Handling (A)